- Trials with a EudraCT protocol (402)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
402 result(s) found for: Systolic heart failure.
Displaying page 1 of 21.
EudraCT Number: 2020-005893-93 | Sponsor Protocol Number: 00909043 | Start Date*: 2021-09-21 | |||||||||||
Sponsor Name:Uniwersytet Medyczny w Białymstoku | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled study evaluating levosimendan re-infusions in patients with severe heart failure with reduced left ventricular ejection fraction. | |||||||||||||
Medical condition: Ambulatory Heart Failure Patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004487-22 | Sponsor Protocol Number: BMI 001 / SMR-1389 | Start Date*: 2005-11-25 | |||||||||||
Sponsor Name:Bio-Medisinsk Innovasjon AS | |||||||||||||
Full Title: A Proof of Biological Efficacy Study Assessing the Potential of Piboserod a Specific 5-HT4 Antagonist for the Treatment of Symptomatic Congestive Heart Failure in stable outpatients NYHA class II-I... | |||||||||||||
Medical condition: Congestive heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001109-28 | Sponsor Protocol Number: pgrf/141/09 | Start Date*: 2008-05-23 | |||||||||||||||||||||
Sponsor Name:University of Aberdeen | |||||||||||||||||||||||
Full Title: Perhexiline therapy in patients with heart failure with preserved left ventricular ejection fraction(HFpEF syndrome) | |||||||||||||||||||||||
Medical condition: Heart failure with preserved left ventricular ejection fraction | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-002688-31 | Sponsor Protocol Number: ICOR-2022-04-LEVOMEMS | Start Date*: 2023-01-25 | ||||||||||||||||||||||||||
Sponsor Name:Germans Trias i Pujol Health Research Institute | ||||||||||||||||||||||||||||
Full Title: LEVO-MEMS: COMPARISION OF THE HAEMODINAMIC PROFILE OF DOBUTAMIN AND LEVOSIMENDAN IN THE CURRENT THERAPEUTICAL CONTEXT | ||||||||||||||||||||||||||||
Medical condition: Heart failure patients with depressed left ventricular ejection fraction | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000068-40 | Sponsor Protocol Number: FAIR-HF2 | Start Date*: 2017-01-27 | |||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality. Ferric carboxymaltose Assessment of morbidity and mortality in patients with IRon de... | |||||||||||||
Medical condition: Systolic heart failure associated with iron deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) PT (Completed) SI (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001971-30 | Sponsor Protocol Number: CLCZ696B2317 | Start Date*: 2014-11-22 | |||||||||||
Sponsor Name:Novartis Pharma services AG | |||||||||||||
Full Title: A multicenter study to evaluate safety and tolerability in patients with chronic heart failure and reduced ejection fraction from PARADIGM-HF receiving open label LCZ696 | |||||||||||||
Medical condition: Heart failure with reduced ejection fraction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) LT (Completed) FI (Completed) NL (Completed) CZ (Completed) SE (Completed) SK (Completed) HU (Completed) PT (Completed) DK (Completed) EE (Completed) ES (Completed) IT (Completed) DE (Completed) BE (Completed) BG (Completed) FR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002468-26 | Sponsor Protocol Number: DKprotokol(LIVE)v5 | Start Date*: 2011-08-12 | |||||||||||
Sponsor Name:Allan Flyvbjerg | |||||||||||||
Full Title: Liraglutide in chronic heart failure. A randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and witho... | |||||||||||||
Medical condition: Primary objective: To investigate the effect of Liraglutide 1.8 mg once daily compared to placebo on left ventricular eject fraction in Chromic heart failure patients with and without Type 2 diabe... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000833-35 | Sponsor Protocol Number: CRLX030A2201 | Start Date*: 2011-10-24 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, phase II, double blind, randomized, parallel group, placebo-controlled study to evaluate the hemodynamic responses to intravenous RLX030 infusion in subjects with acute heart failure. | |||||||||||||
Medical condition: Acute Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) IT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006337-19 | Sponsor Protocol Number: R5381-HF-2159 | Start Date*: 2022-06-08 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of REGN5381, an NPR1 Agonis... | |||||||||||||
Medical condition: Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004805-29 | Sponsor Protocol Number: 201200480529 | Start Date*: 2013-06-04 | |||||||||||
Sponsor Name:The Heart Center, Rigshospitalet | |||||||||||||
Full Title: Beta 3 agonist treatment in heart failure (BEAT-HF) | |||||||||||||
Medical condition: Systolic heart failure | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001588-37 | Sponsor Protocol Number: CRLX030A2202 | Start Date*: 2011-11-29 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the renal hemodynamic effects of RLX030 at a dose of 30 μg/kg/day or placebo infused for 24 hours in su... | |||||||||||||
Medical condition: Chronic heart failure with worsening of symptoms like shortness of breath at rest or minimal exertion | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001560-19 | Sponsor Protocol Number: CSCC-ASC2 | Start Date*: 2015-06-29 | |||||||||||
Sponsor Name:Department of Cardiology, Rigshospitalet | |||||||||||||
Full Title: Allogeneic adipose tissue-derived stromal/stem cell therapy in patients with ischemic heart disease and heart failure | |||||||||||||
Medical condition: Ischemic heart disease and heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005607-92 | Sponsor Protocol Number: QUIDHF_v3.0_20161130 | Start Date*: 2016-08-04 | |||||||||||
Sponsor Name:QUANTUM GENOMICS | |||||||||||||
Full Title: A Phase II randomized, placebo controlled, double-blind, multi-centre study to assess safety and efficacy of incremental doses of QGC001 in patients upon discharge or following hospitalization for ... | |||||||||||||
Medical condition: Patient with worsening chronic heart failure with left ventricular systolic dysfunction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) NO (Completed) GB (Prematurely Ended) PL (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002522-23 | Sponsor Protocol Number: BAY1067197/16782 | Start Date*: 2013-12-20 | |||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||
Full Title: A double blinded, placebo controlled, study to investigate the safety, tolerability, pharmacokinetics and acute cardiovascular responses of a 7 day oral treatment with the partial adenosine A1 rece... | |||||||||||||
Medical condition: Chronic systolic heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000771-24 | Sponsor Protocol Number: CXL-1427-02 | Start Date*: 2014-12-22 | |||||||||||
Sponsor Name:Cardioxyl Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6-Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients with Systolic Heart Failure | |||||||||||||
Medical condition: Heart failure with reduced ejection fraction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000805-27 | Sponsor Protocol Number: MEIN/10/Ran-Did/001 | Start Date*: 2012-10-23 | |||||||||||
Sponsor Name:Menarini International Operations Luxembourg S.A., Avenue de la Gare, 1611 Luxembourg, Luxembourg | |||||||||||||
Full Title: Effect of Ranolazine in Heart Failure Patients with Preserved Ejection Fraction | |||||||||||||
Medical condition: Heart failure patients with preserved ejection fraction (HFpEF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005077-39 | Sponsor Protocol Number: BBLOQ-2017 | Start Date*: 2018-06-12 | |||||||||||
Sponsor Name:Instituto de Investigación Sanitaria INCLIVA | |||||||||||||
Full Title: Betablockers Withdrawal in Patients with Heart Failure with Preserved Ejection Fraction and Chronotropic Incompetence: Effect on Functional Capacity and life quality | |||||||||||||
Medical condition: Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001287-34 | Sponsor Protocol Number: BAY1067197/16718 | Start Date*: 2013-11-04 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A single blind, placebo controlled pilot study to explore the safety and tolerability of a single oral dose of 30 mg BAY 1067197 in patients with chronic heart failure on the background of preexist... | |||||||||||||
Medical condition: Heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000885-39 | Sponsor Protocol Number: 02289 | Start Date*: 2021-01-12 | |||||||||||
Sponsor Name:Universitätsmedizin Göttingen | |||||||||||||
Full Title: Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure | |||||||||||||
Medical condition: Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2023-001004-33 | Sponsor Protocol Number: CLCZ696B2319E2 | Start Date*: 2025-01-20 | |||||||||||
Sponsor Name:Novartis Pharmaceuticals | |||||||||||||
Full Title: A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study | |||||||||||||
Medical condition: Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
